In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read More
In a nutshell This study looks at how often patients being treated for non-Hodgkin lymphoma develop pneumonitis, a swelling of the lungs. The study concluded that patients being treated with R-CDOP chemotherapy are at the highest risk of developing pneumonitis. Some background Pneumonitis is a dangerous and potentially deadly swelling of the...
Read More
In a nutshell This study investigated whether interim FDG PET/CT scanning during chemotherapy helps predict risk for new DLBCL (diffuse large B-cell lymphoma) patients. This study concluded that this scanning improves the risk classifications used to predict outcomes for DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most...
Read More
In a nutshell This study investigated the impact of liposomal doxorubicin (Adriamycin) on cardiac side effects in lymphoma patients compared to conventional doxorubicin. The study suggested that liposomal doxorubicin can reduce cardiac effects and still be an effective therapy, particularly for patients at high risk for anthracycline-induced...
Read More
In a nutshell This study looked at the effectiveness of chemotherapy followed by a single dose of radio-immunotherapy for treating patients with mantle cell lymphoma. The study concluded that radio-immunotherapy after standard chemotherapy is safe and effective to treat patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL)...
Read More
In a nutshell This study looked at the outcomes of patients with relapsed follicular lymphoma who were treated with allogeneic stem cell transplantation. The authors concluded that allogeneic stem cell transplantation is an effective treatment, and is most effective when treating earlier phases of the disease. Some background Follicular...
Read MoreIn a nutshell This study analyzed the medical records of DLBCL patients who received consolidative radiotherapy (RT) after chemotherapy to determine if consolidative RT improved survival. This study concluded that consolidative RT might improve survival in DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read More
In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...
Read More
Cherry Hughes** is an active, energetic 75 year old, still working in the marketing and public relations profession in Great Britain. Her life is filled with friends and fun. “I love cooking and eating out. I am deeply interested in politics. I love music …I go to jazz clubs. I love going to France …I have a little apartment...
Read More
In a nutshell This study looked at the effect of surveillance scans after autologous stem cell transplantation (auto-SCT) in patients with relapsed or refractory diffuse large B-cell lymphoma. The study concluded that scanning everyone after auto-SCT has little benefit. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read More
In a nutshell This study investigated the long-term outcomes of MCL (mantle cell lymphoma) patients who received RIST (reduced-intensity allogenic stem cell transplant) therapy. The authors concluded that RIST may be curative in MCL patients, even in those who relapsed after autoSCT (autologous stem cell transplant). Some background Mantle cell...
Read More
In a nutshell This study compared the safety and effectiveness of R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisone) to CHOP-RIT (CHOP followed by iodine-133-tositumomab, Bexxar) as a first-line treatment for follicular lymphoma (FL) patients. This study concluded that immunochemotherapy should remain the standard...
Read More
